Table 1.
Prevalence of the Most-Common Glucose-Lowering Medication Class Patterns for U.S. Community-Dwelling and Nursing Home Subpopulations Aged 65 and Older, 2007–10
| Community, n = 1,119,874 |
Nursing Home, n = 95,841 |
|||||
|---|---|---|---|---|---|---|
| Rank | Pattern | n | % (95% CI) | Pattern | n | % (95% CI) |
| 1 | Biguanide | 247,920 | 22.14 (22.06–22.22) | Sulfonylurea | 7,729 | 8.06 (7.89–8.24) |
| 2 | Biguanide + sulfonylurea | 158,482 | 14.15 (14.09–14.22) | Short-acting insulin | 6,678 | 6.97 (6.81–7.13) |
| 3 | Sulfonylurea | 138,560 | 12.37 (12.31–12.43) | Biguanide | 5,372 | 5.61 (5.46–5.75) |
| 4 | Biguanide + sulfonylurea + thiazolidinedione | 49,248 | 4.40 (4.36–4.44) | Rapid- + long-acting insulin | 5,080 | 5.30 (5.16–5.44) |
| 5 | Biguanide + thiazolidinedione | 30,590 | 2.73 (2.70–2.76) | Short- + long-acting insulin | 4,124 | 4.30 (4.18–4.43) |
| 6 | Rapid- + long-acting insulin | 30,002 | 2.68 (2.65–2.71) | Biguanide + sulfonylurea | 3,749 | 3.91 (3.79–4.04) |
| 7 | Sulfonylurea + thiazolidinedione | 28,315 | 2.53 (2.50–2.56) | Rapid- + short- + long-acting insulin | 3,272 | 3.41 (3.30–3.53) |
| 8 | Thiazolidinedione | 25,904 | 2.31 (2.29–2.34) | Sulfonylurea+ short-acting insulin | 3,079 | 3.21 (3.10–3.33) |
| 9 | Short-acting insulin | 19,401 | 1.73 (1.71–1.76) | Rapid-acting insulin | 2,569 | 2.68 (2.58–2.78) |
| 10 | Biguanide + sulfonylurea + dipeptidyl peptidase-4 inhibitor | 16,991 | 1.52 (1.49–1.54) | Long-acting insulin | 2,105 | 2.20 (2.10–2.29) |
| 11 | Biguanide + sulfonylurea + long-acting insulin | 16,029 | 1.43 (1.41–1.45) | Biguanide + sulfonylurea + short-acting insulin | 2,031 | 2.12 (2.03–2.21) |
| 12 | Long-acting insulin | 13,488 | 1.20 (1.18–1.22) | Sulfonylurea + short-+ long-acting insulin | 1,919 | 2.00 (1.92–2.09) |
| 13 | Rapid-acting insulin | 12,691 | 1.13 (1.11–1.15) | Biguanide + short-acting insulin | 1,773 | 1.85 (1.77–1.94) |
| 14 | Sulfonylurea + long-acting insulin | 11,284 | 1.01 (0.99–1.03) | Short- + intermediate-acting insulin | 1,649 | 1.72 (1.64–1.80) |
| 15 | Biguanide + dipeptidyl peptidase-4 inhibitor | 10,624 | 0.95 (0.93–0.97) | Sulfonylurea + rapid-+ long-acting insulin | 1,584 | 1.65 (1.57–1.74) |
| 16 | Biguanide + sulfonylurea + thiazolidinedione + dipeptidyl peptidase-4 inhibitor | 10,125 | 0.90 (0.89–0.92) | Rapid- + short-acting insulin | 1,484 | 1.55 (1.47–1.63) |
| 17 | Biguanide + long-acting insulin | 9,858 | 0.88 (0.86–0.90) | Sulfonylurea + rapid- + short- + long-acting insulin | 1,346 | 1.40 (1.33–1.48) |
| 18 | Biguanide + rapid- + long-acting insulin | 9,705 | 0.87 (0.85–0.88) | Biguanide + sulfonylurea + short- + long-acting insulin | 1,287 | 1.34 (1.27–1.42) |
| 19 | Sulfonylurea + dipeptidyl peptidase-4 inhibitor | 8,485 | 0.76 (0.74–0.77) | Thiazolidinedione | 1,236 | 1.29 (1.22–1.36) |
| 20 | Biguanide + sulfonylurea + rapid- + long-acting insulin | 7,909 | 0.71 (0.69–0.72) | Sulfonylurea + rapid-acting insulin | 1,187 | 1.24 (1.17–1.31) |
| >20 | All other patterns | 264,263 | 23.60 (23.52–23.68) | All other patterns | 36,588 | 38.18 (37.87–38.48) |
CI = confidence interval.